Experts in Las Vegas who participated in clinical trials of aducanumab, approved Monday by the FDA, say it is the first drug that appears to slow “the disease process itself.”
Search results for:
The two-week moving average of new cases held steady at 114 per day, while the state test positivity rate dropped to 3.5 percent, according to state data posted Monday.
Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers.